Hypermethylation of cell-free serum DNA indicates worse outcome in patients with bladder cancer.

[1]  Yair Lotan,et al.  Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. , 2006, The Journal of urology.

[2]  Inke Näthke,et al.  Cytoskeleton out of the cupboard: colon cancer and cytoskeletal changes induced by loss of APC , 2006, Nature Reviews Cancer.

[3]  S. Goodman,et al.  Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. , 2006, Journal of the National Cancer Institute.

[4]  S. Cross,et al.  Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma , 2006, The Journal of pathology.

[5]  R. Figlin,et al.  Tobacco smoking, GSTP1 polymorphism, and bladder carcinoma , 2005, Cancer.

[6]  Peter A. Jones,et al.  Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma. , 2005, European journal of cancer.

[7]  Kazuhiro Yoshida,et al.  DNA methylation of genes linked to retinoid signaling in squamous cell carcinoma of the esophagus: DNA methylation of CRBP1 and TIG1 is associated with tumor stage , 2005, Cancer science.

[8]  I. Wistuba,et al.  Aberrant methylation of Reprimo in human malignancies , 2005, International journal of cancer.

[9]  B. Trock,et al.  Preoperative Serum DNA GSTP1 CpG Island Hypermethylation and the Risk of Early Prostate-Specific Antigen Recurrence Following Radical Prostatectomy , 2005, Clinical Cancer Research.

[10]  Ishtiaq Rehman,et al.  Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  W. El-Rifai,et al.  CpG island methylation in Schistosoma- and non-Schistosoma-associated bladder cancer , 2004, Modern Pathology.

[12]  J. Califano,et al.  Quantitative Detection of Promoter Hypermethylation of Multiple Genes in the Tumor, Urine, and Serum DNA of Patients with Renal Cancer , 2004, Cancer Research.

[13]  R. Uzzo,et al.  Detection of Bladder Cancer in Urine by a Tumor Suppressor Gene Hypermethylation Panel , 2004, Clinical Cancer Research.

[14]  M. Villalobos,et al.  Assessing the use of p16(INK4a) promoter gene methylation in serum for detection of bladder cancer. , 2002, European urology.

[15]  Chun Jing,et al.  Tazarotene-induced gene 1 (TIG1) expression in prostate carcinomas and its relationship to tumorigenicity. , 2002, Journal of the National Cancer Institute.

[16]  Jose M. Silva,et al.  p14ARF promoter hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  K. To,et al.  Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  J. Minna,et al.  Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. , 2001, Cancer research.

[19]  J. Herman,et al.  A gene hypermethylation profile of human cancer. , 2001, Cancer research.

[20]  A. Garin,et al.  Genetic analysis of DNA excreted in urine: a new approach for detecting specific genomic DNA sequences from cells dying in an organism. , 2000, Clinical chemistry.